{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died","groupId":"OG000","lowerLimit":"4.4","upperLimit":"NA","value":"9.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"DOR was defined as the time from an initial objective response (CR or PR) per RECIST v1.1 until the first observation of documented disease progression (PD), as determined by ICR, or death due to any cause. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).","id":"OG000","title":"Retifanlimab 500 mg"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set. All participants with confirmed tumor responses (CR or PR) by ICR according to RECIST v1.1 were analyzed. The 95% confidence interval was calculated using the Brookmeyer and Crowley's method and Klein and Moeschberger's method with log-log transformation.","reportingStatus":"POSTED","timeFrame":"up to 18.2 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}